Tags

Type your tag names separated by a space and hit enter

Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients.
J Gastroenterol. 2004 Jan; 39(1):56-60.JG

Abstract

BACKGROUND

In pancreatic cancers, K-ras mutations have been found frequently (80%-100%), and they could be a good marker to detect tumor DNA in the plasma. Several studies have indicated that polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) analysis of K-ras mutation was a useful method for the detection of hepatic and lymph node metastasis of pancreatic cancer. However, this method sometimes exhibited false-positive results, and the rate of K-ras mutation might thus be overestimated in these tissues. To diagnose pancreatic cancer correctly at an early stage, we attempted to detect tumor DNA in the plasma of pancreatic cancer patients using a more sensitive and specific method.

METHODS

We examined 28 pancreatic cancer patients using a sensitive mutation-specific mismatch ligation assay for K-ras gene mutations in primary tumors and paired plasma samples.

RESULTS

K-ras gene mutations were detected in 26 of the 28 (93%) pancreatic cancers. We also found the same mutations in 9 of these 26 (35%) patients in their plasma DNA. This mutation was found even in the plasma of patients with TNM stage II cancer.

CONCLUSIONS

Genetic alterations present in the tumors of pancreatic cancer patients can be detected in their plasma, and this approach is potentially applicable for cancer screening and the monitoring of this deadly disease.

Authors+Show Affiliations

Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

14767735

Citation

Uemura, Takanori, et al. "Detection of K-ras Mutations in the Plasma DNA of Pancreatic Cancer Patients." Journal of Gastroenterology, vol. 39, no. 1, 2004, pp. 56-60.
Uemura T, Hibi K, Kaneko T, et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol. 2004;39(1):56-60.
Uemura, T., Hibi, K., Kaneko, T., Takeda, S., Inoue, S., Okochi, O., Nagasaka, T., & Nakao, A. (2004). Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. Journal of Gastroenterology, 39(1), 56-60.
Uemura T, et al. Detection of K-ras Mutations in the Plasma DNA of Pancreatic Cancer Patients. J Gastroenterol. 2004;39(1):56-60. PubMed PMID: 14767735.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. AU - Uemura,Takanori, AU - Hibi,Kenji, AU - Kaneko,Tetsuya, AU - Takeda,Shin, AU - Inoue,Soichiro, AU - Okochi,Osamu, AU - Nagasaka,Tetsuro, AU - Nakao,Akimasa, PY - 2003/01/14/received PY - 2003/05/02/accepted PY - 2004/2/10/pubmed PY - 2004/5/15/medline PY - 2004/2/10/entrez SP - 56 EP - 60 JF - Journal of gastroenterology JO - J Gastroenterol VL - 39 IS - 1 N2 - BACKGROUND: In pancreatic cancers, K-ras mutations have been found frequently (80%-100%), and they could be a good marker to detect tumor DNA in the plasma. Several studies have indicated that polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) analysis of K-ras mutation was a useful method for the detection of hepatic and lymph node metastasis of pancreatic cancer. However, this method sometimes exhibited false-positive results, and the rate of K-ras mutation might thus be overestimated in these tissues. To diagnose pancreatic cancer correctly at an early stage, we attempted to detect tumor DNA in the plasma of pancreatic cancer patients using a more sensitive and specific method. METHODS: We examined 28 pancreatic cancer patients using a sensitive mutation-specific mismatch ligation assay for K-ras gene mutations in primary tumors and paired plasma samples. RESULTS: K-ras gene mutations were detected in 26 of the 28 (93%) pancreatic cancers. We also found the same mutations in 9 of these 26 (35%) patients in their plasma DNA. This mutation was found even in the plasma of patients with TNM stage II cancer. CONCLUSIONS: Genetic alterations present in the tumors of pancreatic cancer patients can be detected in their plasma, and this approach is potentially applicable for cancer screening and the monitoring of this deadly disease. SN - 0944-1174 UR - https://www.unboundmedicine.com/medline/citation/14767735/Detection_of_K_ras_mutations_in_the_plasma_DNA_of_pancreatic_cancer_patients_ L2 - https://dx.doi.org/10.1007/s00535-003-1245-1 DB - PRIME DP - Unbound Medicine ER -